Autoimmune Dysautonomia Evaluation

Clinical Utility of Autoimmune Dysautonomia Evaluation

July 2012

Seropositivity can help distinguish autoimmune dysautonomia from chemotherapy side effects.  Finally, a rise in antibody titer in a previously seropositive patient can suggest cancer recurrence.

< Previous Slide

Clinical Utility

Next Slide >

 

Jump to section:

• Introduction
• New Profile
• Autoimmune Dysautonomia
• Autoimmune Dysautonomia
• Autoimmune Dysautonomia^1,2
• Pandysautonomia
• Limited Dysautonomia³
• Objective Testing
• Thermoregulatory Sweat Testing: Measuring Heat-Induced Sweating
• Antibody Testing in Autoimmune Dysautonomia
• Antibody Testing in Autoimmune Dysautonomia
• Ganglionic Acetylcholine Receptor (AChR) Autoantibody
• Ganglionic AChR Autoantibody
• Autoimmune Dysautonomia Antibody Profile
• ADE/89904 Autoimmune Dysautonomia Evaluation, Serum Algorithm
• ADE/89904 Autoimmune Dysautonomia Evaluation, Serum Algorithm
• ADE/89904 Autoimmune Dysautonomia Evaluation, Serum Algorithm
• ADE/89904 Autoimmune Dysautonomia Evaluation, Serum Algorithm
• Clinical Utility of Autoimmune Dysautonomia Evaluation
• Clinical Utility of Autoimmune Dysautonomia Evaluation
• Summary
• References
• Questions